Free Trial

Adam S. Grossman Sells 100,000 Shares of ADMA Biologics, Inc. (NASDAQ:ADMA) Stock

ADMA Biologics logo with Medical background

ADMA Biologics, Inc. (NASDAQ:ADMA - Get Free Report) CEO Adam S. Grossman sold 100,000 shares of the firm's stock in a transaction dated Friday, June 14th. The shares were sold at an average price of $10.72, for a total value of $1,072,000.00. Following the sale, the chief executive officer now owns 2,081,475 shares of the company's stock, valued at $22,313,412. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link.

ADMA Biologics Stock Performance

NASDAQ ADMA traded down $0.15 during trading hours on Friday, reaching $10.63. The company's stock had a trading volume of 2,385,813 shares, compared to its average volume of 2,762,370. The company has a current ratio of 5.21, a quick ratio of 1.86 and a debt-to-equity ratio of 0.91. The business has a 50-day simple moving average of $8.17 and a 200 day simple moving average of $6.19. ADMA Biologics, Inc. has a 52 week low of $3.06 and a 52 week high of $10.85. The stock has a market cap of $2.46 billion, a PE ratio of -531.50 and a beta of 0.48.

ADMA Biologics (NASDAQ:ADMA - Get Free Report) last issued its earnings results on Thursday, May 9th. The biotechnology company reported $0.08 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $0.05 by $0.03. The firm had revenue of $81.90 million for the quarter, compared to analysts' expectations of $77.28 million. ADMA Biologics had a negative net margin of 1.29% and a positive return on equity of 17.24%. ADMA Biologics's revenue was up 43.9% on a year-over-year basis. During the same quarter last year, the company posted ($0.03) earnings per share. Equities research analysts predict that ADMA Biologics, Inc. will post 0.35 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

ADMA has been the subject of several recent analyst reports. HC Wainwright raised their target price on ADMA Biologics from $7.50 to $10.00 and gave the company a "buy" rating in a research note on Friday, May 10th. Raymond James lifted their price target on ADMA Biologics from $8.00 to $10.00 and gave the stock a "strong-buy" rating in a research note on Friday, May 10th. Mizuho raised their target price on shares of ADMA Biologics from $10.00 to $12.00 and gave the stock a "buy" rating in a report on Friday, May 10th. Finally, Cantor Fitzgerald raised their target price on shares of ADMA Biologics from $8.00 to $10.00 and gave the stock an "overweight" rating in a report on Friday, May 10th. One equities research analyst has rated the stock with a hold rating, three have given a buy rating and one has issued a strong buy rating to the company. According to data from MarketBeat, the company has a consensus rating of "Buy" and an average target price of $10.50.


Check Out Our Latest Analysis on ADMA Biologics

Institutional Investors Weigh In On ADMA Biologics

A number of hedge funds have recently made changes to their positions in the business. Castleark Management LLC bought a new stake in shares of ADMA Biologics during the first quarter valued at approximately $5,400,000. Caxton Associates LP raised its holdings in shares of ADMA Biologics by 1,876.3% during the first quarter. Caxton Associates LP now owns 389,191 shares of the biotechnology company's stock valued at $2,569,000 after buying an additional 369,498 shares during the last quarter. Bellevue Group AG bought a new stake in shares of ADMA Biologics during the first quarter valued at approximately $270,000. Price T Rowe Associates Inc. MD raised its holdings in shares of ADMA Biologics by 13.9% during the first quarter. Price T Rowe Associates Inc. MD now owns 60,924 shares of the biotechnology company's stock valued at $403,000 after buying an additional 7,450 shares during the last quarter. Finally, Lazard Asset Management LLC raised its holdings in shares of ADMA Biologics by 5.5% during the first quarter. Lazard Asset Management LLC now owns 110,809 shares of the biotechnology company's stock valued at $730,000 after buying an additional 5,731 shares during the last quarter. Institutional investors own 75.68% of the company's stock.

ADMA Biologics Company Profile

(Get Free Report)

ADMA Biologics, Inc, a biopharmaceutical company, engages in developing, manufacturing, and marketing specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases in the United States and internationally. The company offers BIVIGAM, an intravenous immune globulin (IVIG) product indicated for the treatment of primary humoral immunodeficiency (PI); ASCENIV, an IVIG product for the treatment of PI; and Nabi-HB for the treatment of acute exposure to blood containing Hepatitis B surface antigen and other listed exposures to Hepatitis B.

See Also

Insider Buying and Selling by Quarter for ADMA Biologics (NASDAQ:ADMA)

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.

Should you invest $1,000 in ADMA Biologics right now?

Before you consider ADMA Biologics, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and ADMA Biologics wasn't on the list.

While ADMA Biologics currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

5G Stocks: The Path Forward is Profitable Cover

Click the link below and we'll send you MarketBeat's guide to investing in 5G and which 5G stocks show the most promise.

Get This Free Report
Like this article? Share it with a colleague.

Featured Articles and Offers

Recent Videos

CPI News Breakdown: Key Market Moves to Follow
Understanding Oversold Stocks
Inside Pelosi’s Latest Stock Moves

Stock Lists

All Stock Lists

Investing Tools

Calendars and Tools

Search Headlines